Safety of allergen-specific sublingual immunotherapy and nasal immunotherapy

Chemical Immunology and Allergy

Volumn 82, Issue , 2003, Pages 109-118

  Passalacqua, Giovanni ^a,b   Fumagalli, Federica ^a   Guerra, Laura ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Local nasal immunotherapy; Safety; Side effects; Sublingual immunotherapy

Indexed keywords

ALLERGEN; BIRCH POLLEN EXTRACT; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; OLIVE TREE EXTRACT; PARIETARIA EXTRACT; UNCLASSIFIED DRUG;

ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATALITY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; RHINORRHEA; SIDE EFFECT; STOMACH PAIN; URTICARIA; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); DESENSITIZATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MOUTH MUCOSA; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; MOUTH MUCOSA;

EID: 0347884163     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071545     Document Type: Review

References (57)

1. Noon L: Prophylactic inoculation against hay fever. Lancet 1911;i:1572-1573.
2. Black JH: The oral administration of pollen: Clinical report. J Lab Clin Med 1928;13:709.
3. Dunbar P: The present state of knowledge of hayfever. J Hyg 1913;13:105.
4. Passalacqua G, Albano M, Riccio A, et al: Local nasal immunotherapy: Experimental evidences and general considerations. Allergy 1997;52(33 suppl):10-16.
5. Herxeimer H: Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol 1951;40:40-57.
6. Committee on the Safety of Medicines. CSM update. Desensitizing vaccines. Br Med J 1986;293:948.
7. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC: Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987;79:660-677.
8. Reid MJ, Lockey RF, Turkeltaub PC, Platt-Mills TAE: Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993;92:6-15.
9. Rogala B: Risk and safety of specific immunotherapy. Allergy 1998;53:473-477.
10. Malling HJ, Weeke B: EAACI immunotherapy position paper. Allergy 1993;48(suppl 14):9-35.
11. World Health Organization Position Paper: Allergen immunotherapy: Therapeutical vaccines for allergic diseases. Allergy 1998;53(suppl 44):20-22.
12. Malling HJ: EAACI position paper on local immunotherapy. Allergy 1998;53:933-944.
13. ARIA: Allergic rhinitis and its impact on asthma. Position paper endorsed by WHO. J Allergy Clin Immunol 2001;108(suppl):240-245.
14. Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol 1990;18:277-284.
15. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H: A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309-313.
16. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC: Sublingual immunotherapy in Parietaria pollen-induced rhinitis: A double blind study. J Investig Allergol Clin Immunol 1995;5:25-30.
17. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP: Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995;23:173-178.
18. Hirsch T, Sahn M, Leupold W: Double blind placebo controlled study of sublingual immunotherapy with house dust mite extracts in children. Pediatr Allergy Immunol 1997;8:21-27.
19. Clavel R, Bousquet J, André C: Clinical efficacy of sublingual swallow immunotherapy: A double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998;53:493-498.
20. Horak F, Stubner UE, Berger U, Marks B, Toth J, Jager S: Immunotherapy with sublingual birch pollen extract: A short-term double-blind study. J Investig Allergol Clin Immunol 1998;8:165-171.
21. Vourdas D, Syrigou E, Potamianou P, et al: Double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998;53:662-671.
22. Hordijk GJ, Antwelink JB, Luwema RA: Sublingual immunotherapy with a standardized grass pollen extract: A double-blind placebo-controlled study. Allergol Immunopathol 1998;26:234-240.
23. Passalacqua G, Albano M, Fregonese L, et al: Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis. Lancet 1998;351:629-632.
24. Passalacqua G, Albano M, Riccio AM, et al: Clinical and immunological effects of a rush sublingual immunotherapy to Parietaria species: A double-blind placebo-controlled trial. J Allergy Clin Immunol 1999;104:964-968.
25. Bousquet J, Scheinmann P, Guinnepain MT, et al: Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: A double-blind placebo-controlled study. Allergy 1999;54:249-260.
26. Purello D'Ambrosio F, Gangemi S, Isola S, et al: Sublingual immunotherapy: A double-blind placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999;54:968-973.
27. Pradalier A, Basset D, Claudel A, et al: Sublingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999;54:819-828.
28. La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW: Double-blind placebo-controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425-432.
29. Guez S, Vatrinet C, Fadel R, André C: House dust mite sublingual swallow immunotherapy in perennial rhinitis: A double-blind placebo-controlled study. Allergy 2000;55:369-375.
30. Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunological effects of long-term sublingual immunotherapy in asthmatic children sensitized to mite: A double-blind study. Allergy 2000;55:842-849.
31. Caffarelli C, Sensi LG, Marcucci F, Cavagni C: Preseasonal local allergoid immunotherapy to grass pollen in children: A double-blind, placebo-controlled, randomized trial. Allergy 2000;55:1142-1147.
32. Ariano R, Spadolini I, Panzani RC: Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double-blind study. Allergol Immunopathol (Madr) 2001;29:238-244.
33. Bahceciler NN, Isik U, Barlan IB, Basaran N: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49-55.
34. Voltolini S, Modena P, Minale P, et al: Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardized extract of tree pollen (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madr) 2001;29:103-110.
35. Lima MT, Watson D, Pitkin L, et al: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: A randomized controlled trial. Clin Exp Allergy 2002;32:507-514.
36. André C, Vatrinet C, Galvain S, Carat F, Sicard H: Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000;121:229-234.
37. Quirino T, Iemoli E, Siciliani E, Parmiani S: Sublingual vs injective immunotherapy in grass pollen allergic patients: A double-blind double-dummy study. Clin Exp Allergy 1996;26:1253-1261.
38. Khinchi S, Poulsen LK, Carat F, André C, Malling HJ: Clinical efficacy of sublingual swallow and subcutaneous immunotherapy in patients with allergic rhinoconjunctivitis due to birch pollen. A double-blind double-dummy placebo-controlled study. 19th EAACI Congress, Lisbon (abstract). Allergy 2000;55(suppl 63):24.
39. Tinkelman DG, Cole WQ, Tunno J: Immunotherapy: A one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995;95:8-14.
40. Ostergaard PA, Kaad PH, Kristensen T: A prospective study on the safety of immunotherapy in children with severe asthma. Allergy 1986;41:588-593.
41. Stewart GE, Lockey RF: Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:567-578.
42. Malling HJ: Immunotherapy as an effective tool in allergy treatment. Allergy 1998;53:461-472.
43. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC: Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(suppl 1):47-55.
44. Lower T, Hensy J, Mandik L, et al: Compliance with allergen immunotherapy. Ann Allergy 1993;70:480-482.
45. Cohn JR, Pizzi A: Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734-737.
46. Almangro E, Assensio O, Bartolomé JM, et al: Estudio multicentrico de farmacovigilancia de imunoterapia sublingual en pacientes alergicos. Allergol Immunopathol 1995;23:153.
47. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW: Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999;54:1110-1113.
48. Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW, Passalacqua G: Safety of sublingual immunotherapy in adults: A post-marketing surveillance study. Allergy 2001;56:889-892.
49. Lombardi C, Canonica GW, Passalacqua G: Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy 2000;55:677-678.
50. Frati F, Marcucci F, Sensi L, Passalacqua G: Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy: Safety and immunological implications. Allergy 2001;56:1091-1095.
51. Bagnasco M, Passalacqua G, Villa G, et al: Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001;31:54-60.
52. Bagnasco M, Mariani G, Passalacqua G, et al: Absorption and distribution kinetics of the major Parietaria allergen (Par j 1) administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997;100:122-129.
53. Passalacqua G, Albano M, Pronzato C, Riccio A, Falagiani P, Canonica GW: Long-term follow-up of nasal immunotherapy to Parietaria: Clinical and immunological effects. Clin Exp Allergy 1997;27:904-908.
54. Bjorksten B: Local immunotherapy is not documented for clinical use. Allergy 1994;49:299-301.
55. Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW: Local immunotherapy: Pharmacokinetics and efficacy. Allergy 1998;53:477-484.
56. D'Amato G, Lobefalo G, Liccardi G, Cazzola M: A double-blind placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995;25:141-148.
57. Frew AJ, Smith PJ: Sublingual immunotherapy. J Allergy Clin Immunol 2001;107:441-444.